Some of the adverse events related to the use of regorafenib often limits its use in clinical practice. A study suggests the usefulness of a more flexible dosing, which improves patients’ quality of life without jeopardizing efficacy.
From https://www.sciencedaily.com/releases/2019/07/190706123457.htm
from
https://healthnews010.wordpress.com/2019/07/07/data-demonstrate-efficacy-of-more-flexible-dose-of-regorafenib-to-relieve-side-effects-in-mcrc-patients/
No comments:
Post a Comment